Development of multi-epitope vaccines targeting wild-type-sequence p53 peptides

Expert Review of Vaccines

Volumn 7, Issue 7, 2008, Pages 1031-1040

  DeLeo, Albert B ^a   Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Dendritic cell; Immunomonitoring; Multi epitope vaccine; p53; T cell; Wild type sequence peptide

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 2; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; ISA 51; PROTEIN P53; TETANUS TOXOID; UNCLASSIFIED DRUG; WT P53 PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; APOPTOSIS; CARDIOTOXICITY; CD4+ T LYMPHOCYTE; CELL PROTECTION; CLINICAL TRIAL; FATIGUE; GENE LOSS; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTOPENIA; MEMORY T LYMPHOCYTE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; VACCINE PRODUCTION; WILD TYPE;

ANIMALS; CANCER VACCINES; EPITOPES; HUMANS; MICE; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; VACCINES, SYNTHETIC;

EID: 51349112211     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.7.1031     Document Type: Review

References (60)

1. Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr. Cancer Drug Targets 7, 633-642 (2007). • Vaccines need to generate long-term survival of tumor-specific immune cells to be clinically beneficial.
2. Morris LF, Ribas A. Therapeutic cancer vaccines. Surg. Oncol. Clin. N. Am. 16, 819-831 (2007).
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor. Nat. Immunol. 3, 991-998 (2002). • Immune system plays a major role in the nature of tumors that arise in humans.
4. Nijman HW, Van der Burg SH. Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol. Lett. 40, 171-178 (1994). • First report identifying cytotoxic T-lymphocyte (CTL)-defined wild-type (wt) p53 peptides for potential vaccine use.
5. Hoffmann TK, Bier H, Donnenberg AD, Whiteside TL, DeLeo AB. p53 as an immuno-therapeutic target in head and neck cancer. Adv. Otorhinolargyngol. 62, 151-160 (2005).
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253, 49-53 (1991). • Describes a vast extent of genetic alterations in p53 in human cancer.
7. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl Cancer Inst. 88, 1442-1455 (1996).
8. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res. 63, 1188-1191 (2003). • Sequencing p53 exons (exons 2-11) as well as the intron/exon junctions required to identify p53 genetic alterations in cancer.
9. De Leo AB. p53-based immunotherapy of cancer. Adv. Otorhinolaryngol. 62, 134-150 (2005). • Overview of the development of p53-based immunotherapy.
10. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc. Natl Acad. Sci. USA 92, 11993-11997 (1995). • Multiple wt p53 peptides identified for vaccines using HLA-A2 transgenic mice.
11. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol. 160, 328-333 (1998).
12. 264-272 peptide-specific CTLs recognize and kill human tumor cells.
13. Vierboom MP, Zwaveling S, Bos GMJ et al. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res. 60, 5508-5513 (2000). • p53 parameters that influence processing and presentation of wt p53 peptides.
14. Allen PM. Making antigens presentable. J. Immunol. 179, 3-4 (2007).
15. Harding CV, Neefjes J. Antigen processing and recognition. Curr. Opin. Immunol. 17, 55-57 (2005).
16. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer. Clin. Cancer Res. 12, 3890-3895 (2006). • Defects in antigen-processing machinery components play a key role in tumor escape.
17. + T-helper cells in anti-tumor immunity.
18. Carbone DP, Ciernik IF, Kelley MJ et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J. Clin. Oncol. 23, 5099-5107 (2005). • Personalized mutant p53 peptide-based vaccines for immunotherapy of patients with cancer.
19. Nijman HW, Houbiers JG Vierboom MP et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23, 1215-1219 (1993).
20. 110-124 peptide is a helper peptide.
21. + T cells. J. Immunol. 177, 6795-6803 (2006). • Identification of a multi-HLA class II-wt p53 peptide for vaccine use.
22. Eura M, Chikamatsu K, Katsura F et al. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin. Cancer Res. 6, 979-986 (2000).
23. + T cells obtained from patients with cancer are responsive in vitro to multiple wt p53 peptides.
24. 264-272 peptide in tumors.
25. Mayordomo JI, Loftus DJ, Sakamoto H et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183, 1357-1365 (1996). • Efficacy of a wt p53 peptide-based vaccine for immunotherapy demonstrated in a preclinical murine tumor model.
26. + T cells.
27. Hernandez J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol. 164, 596-602 (2000).
28. Vierboom MP, Nijman HW, Offringa R et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186, 695-704 (1997).
29. Tuting T, Gambotto A, Robbins PD, Storkus WJ, DeLeo AB. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen b-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther. 6, 629-636 (1999).
30. Hernández J, Ko A, Sherman LA. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol. 166, 3908-3914 (2001).
31. Cicinnati VR, Dworacki G, Albers A et al. Impact of p53-based immunization on primary chemically-induced tumors. Int. J. Cancer 113, 961-970 (2005). • wt p53 peptide-based immunization influences selection of sites of p53 mutation and epitope-loss tumors in chemically induced carcinogenesis in mice.
32. + head-and-neck cancer patients and correlates to sites of p53 mutation and epitope-loss in their tumors.
33. Bourhis J, Lubin R, Roche B et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. Natl Cancer Inst. 88, 1228-1233 (1996).
34. + T cells from cancer patients are responsive in vitro to wt p53 peptides and relationship to p53 status of their tumors.
35. Houbiers JG, van der Burg SH, van de Watering LM et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer 72, 637-641 (1995).
36. Whiteside TL. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine 20, A46-A51 (2002). • High rate of T-cell turnover might have unfavorable effects on immunotherapy.
37. + T cells in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13, 6301-6311 (2007). • Oncologic therapy favors expansion of Tregs.
38. Curiel TJ. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117, 1167-1174 (2007). • Critical need to address the role of Tregs in immunotherapy failures.
39. Gabrilovich DI. Mechanisms and functional significance of tumor-induced dendritic cell differentiation in cancer. Nat. Rev. Immunol. 4, 941-952 (2004).
40. Chikamatsu K, Nakano K, Storkus WJ et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res. 5, 1281-1288 (1999).
41. 149-157 peptide identified for vaccine use.
42. + patients with cancer.
43. + T-helper response against the p53 tumor antigen. Cancer Res. 68, 893-900 (2008).
44. + T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur. J. Immunol. 28, 305-316 (1998).
45. + p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol. Immunother. 54, 1072-1081 (2005).
46. Vence L, Palucka AK, Fay JW et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 104, 20884-20889 (2007). • HLA class II-restricted tumor peptides recognized by antigen-specific Tregs obtained from patients with cancer.
47. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6, 345-352 (2005). • Tregs play a critical role in immunological unresponsiveness to self-antigens.
48. Arias RS, Flanagan ML, Miller KD et al. RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt) 26, 119-130 (2007).
49. Morse MA, Hobeika AC, Osada T et al. Depletion of human regulatory T cells specifically enhances antigen specific immune responses to cancer vaccines. Blood 112(3), 610-618 (2008).
50. + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120, 2723-2733 (2007).
51. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648 (2007).
52. Czystowska M, Szczepanski M, Szajnik M, Whiteside TL. IRX-2, a multi-targeted biologic, protects human T-cells from tumor-induced cell death. Presented at: American Association for Cancer Research, San Diego, CA, USA, 12-16 April 2008 (Abstract #2090).
53. + cells. J. Exp. Med. 195, 1523-1532 (2002).
54. Nikitina EY, Clark JI, Van Beynen J et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin. Cancer Res. 7, 127-135 (2001).
55. Svane IM, Pedersen AE, Johnsen HE et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a Phase I study. Cancer Immunol. Immunother. 53, 633-641 (2004). • First report on results of a wt p53 peptide-based vaccine trial for patients with cancer.
56. Svane IM, Pedersen AE, Johansen JS et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol. Immunother. 56, 1485-1499 (2007).
57. Herrin VE, Achtar MS, Steinberg SM et al. A randomized Phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2007 (Abstract 3011). • Two-arm wt p53 peptide-based vaccine trial for ovarian cancer patients.
58. 65-73 wild type peptide loaded on dendritic cells in vitro, specifically recognized and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand. J. Immunol. 51, 128-133 (2000).
59. McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol. Immunother. 49, 417-425 (2000).
60. Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br. J. Cancer 84, 1052-1057 (2001).